GLENMARK PHARMACEUTICALS Intrinsic Value
GLENMARK · Healthcare · Current price ₹2,448.9
Is GLENMARK PHARMACEUTICALS undervalued?
DocStoX estimates the fair value of GLENMARK PHARMACEUTICALS at ₹1,326 per share, versus the current market price of ₹2,449. That puts the stock about -45.8% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹823), Relative P/E (₹1,887), Graham floor (₹636), Analyst target (₹2,392). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹636 (bear) to ₹1,326 (base) to ₹2,392 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹2,449 versus an intrinsic value of ₹1,326, GLENMARK PHARMACEUTICALS currently offers -45.8% of negative margin (i.e. a premium).
More on GLENMARK PHARMACEUTICALS
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.